

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	Apomorphine hydrochloride
Brand Name	Kynmobi™
Dosage Form(s)	10 mg, 15 mg, 20 mg, 25 mg and 30 mg sublingual films.
Manufacturer	Sunovion Pharmaceuticals Canada Inc
Submission Type	New Submission
Use Reviewed	To treat “OFF” episodes in adults with Parkinson’s disease.
Common Drug Review (CDR)	Yes, CDR recommended: Reimburse . Visit the CDR website for more details: www.cadth.ca/node/88649 .
Provincial Review	The DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry’s drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC screened Kynmobi on September 14, 2020. The DBC advised that because Kynmobi is similar to some of the other drugs used for the treatment “OFF” episodes in adults with Parkinson’s disease, the Ministry may accept the CDEC’s recommendation for Kynmobi.
Drug Coverage Decision	Limited Coverage Benefit Access the Kynmobi criteria from www.gov.bc.ca/pharmacarespecialauthority
Date	June 27, 2022
Reason(s)	Drug coverage decision is consistent with the CDEC recommendation

	<ul style="list-style-type: none"> • The sublingual formulation (Kynmobi) provides an easy-to-use and convenient solution to the administration challenges associated with subcutaneous apomorphine (Movapo), while delivering similar efficacy. • Kynmobi is not contraindicated in patients with Parkinson's disease using concomitant antihypertensive medications or vasodilators, like it is with Movapo. • The pan-Canadian Pharmaceutical Alliance (pCPA) and Business Management were involved in successful negotiations with the manufacturer of this product.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.